DYNAMIC+ Framework: Revolutionizing Data Integrity and Moving Beyond ALCOA+ in Pharma 4.0

Product quality, safety, and effectiveness are the top priorities of biopharmaceutical companies in manufacturing therapeutics (Manzano & Langer, 2018). The pharmaceutical industry, over the last few decades, has focused more on better-quality products in line with evolving Good Manufacturing Practice (GMP) regulations that are essential in every step of drug manufacturing (Steinwandter et al., 2019). Among such regulations, data integrity or the consistency and reliability of data in its lifetime ranks atop. This is for regulation, patient safety, and product quality. The drug regulatory authorities like the FDA and EMA mandate drug manufacturers to possess accurate, complete, and consistent data since inconsistency can present a breeding ground for harmful such as contamination and drug defects. Data integrity is a factor in product quality; inconsistency can lead to improper dosing or missing ingredients, which can be dangerous to patients' health. Furthermore, regulatory bodies expect complete records to ensure safety, efficacy, and legality (Finelli & Narasimhan, 2020). Data integrity is maintained through technical aspects like secure storage of data and organizational controls like training and regular audits to catch inconsistencies early. The FDA, therefore, in response, has come up with the ALCOA+ principles where data must be Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available (FDA report, 2018). The standards provide data integrity form but have been qualitatively assessed for non-metric attributes. Various approaches to achieve ALCOA+ requirements have been outlined, and deviation leads to unnecessary delays and additional costs (Kavasidis et al., 2022). Compliance verification in the contemporary period continues to be burdensome and time-consuming and is often based on a time-consuming questionnaire (Smiatek et al., 2020). Moreover, data in the pharma industry is usually heterogeneous in nature, which makes it cumbersome to manage the data under rigorous requirements for mass and smart production from emerging technologies. With the amount and diversity of data, artificial intelligence methods, and especially deep learning models, provide effective solutions for boosting compliance. The integration of artificial intelligence (AI) with the internet of things (IoTs) represents a significant advancement in pharmaceutical manufacturing and effectively bridges the gap between digital and physical worlds (Kodumuru et al., 2025). Through the evaluation of historical and real-time data, deep learning can forecast compliance and track the health of the production line, being extremely useful in upholding ALCOA+ standards (Alosert et al., 2020). The DYNAMIC+ framework is presented in this article, a cutting-edge and technology-based methodology for guaranteeing data integrity in Pharma 4.0. Expanding ALCOA+, it encompasses additional principles to address automation, cybersecurity, decentralized data management, and AI-driven decision-making. DYNAMIC+ is the second generation of ALCOA+ principles with the addition of AI-based methodologies. This framework facilitates high-end processing of information and handling of increasing raw pharma manufacturing line data with strong regulatory compliance. The key contributions of this work are a new approach for computing compliance, a predictive model for analyzing compliance against ALCOA+ principles.

Figure1. Key Priorities in Biopharmaceutical Therapeutics Manufacturing: Quality, Safety, and Effectiveness

Figure 2. ISA-95 framework for GMP bioprocessing, with examples for each of its five layers.

Figure 3. Data Processing Pipeline for Ensuring Integrity in Bioprocess Manufacturing within Industry 4.0.

Figure 4. Insightful Manufacturing Flow Diagram: Mapping Stages, Data Interactions, and Traceability

5. Technologies Powering DYNAMIC+

The DYNAMIC+ solution is an innovative solution that employs the most advanced technologies to optimize data integrity in the pharma industry. All modules are addressing Pharma 4.0 challenges. Some of the key technologies employed in DYNAMIC+ and their functions in providing safe data integrity solutions are listed below.

5.1. Blockchain for Data Integrity

Blockchain is a foundation of DYNAMIC+, providing a decentralized, tamper-evident ledger that revolutionizes data management. In the pharmaceutical industry, blockchain timestamps all transactions—e.g., clinical trial data and manufacturing history—to prevent tampering. That transparency allows stakeholders, including regulators, to see an unalterable audit trail. Smart contracts impose compliance through rules based on data integrity, minimizing human error and maximizing accountability (Haleem et al., 2019).

5.2. AI and Machine Learning for Compliance

Machine learning and AI revolutionize data management by relying on advanced analytics. The technologies scan massive amounts of data automatically, identifying trends and outliers that indicate compliance risk. Machine learning is able to forecast potential compliance risks, enabling regulatory departments to remediate high-risk items. AI also enables real-time monitoring of processes, which identifies deviations in real time, minimizing risks and enabling ongoing improvement (Padmanaban, 2024).

5.3. Cloud and Edge Computing for Data Access

Cloud and edge computing facilitate real-time access to data between geographically separated pharmaceutical sites. Data is centralized by employing cloud technology for making them available for simultaneous use by geographically separated teams at different locations, as needed for global clinical trials. Edge computing facilitates data to be processed at a geographically closer site, precluding latency while allowing real-time analytics to be performed. Such access strengthens compliance and business flexibility (Singh et al., 2017).

5.4. Security Cybersecurity Frameworks

Like with increasing threats in the cyber world, there is a need for robust cybersecurity to protect sensitive information. Zero-trust models are employed in DYNAMIC+ for rigorous verification of users and devices. Artificial intelligence-based real-time behavioral inspection and anomaly detection detect potential security breaches within a limited time duration, thereby securing data integrity as well as trust of stakeholders. End-to-end encryption also protects data in transit (Pesqueira & Sousa, 2024).

5.5. IoT for Real-Time Monitoring

DYNAMIC+ supports IoT sensors implanted, which aid in real-time monitoring and collection of data within processes. Temperature and humidity monitoring, among such crucial parameters, occur in real time, along with policy compliances being easy to achieve. The feature adds strength to the authenticity of data with real-time deviation notifications. IoT data are stored securely on the blockchain in the form of immutable records too (Ullagaddi, 2024).

DYNAMIC+ resolves data integrity challenges for the pharma sector in general. With blockchain, AI, cloud computing, cybersecurity, and IoT integration, DYNAMIC+ is in a better position to provide compliance and business effectiveness. The new utility has robust levels of data integrity that make for a dynamic, responsive, and resilient industry strong enough to fight adversity in the future.

6. Regulatory Alignment: How DYNAMIC+ Meets FDA, EMA, and Global Data Integrity Standards

With the pharma landscape evolving with newer technologies being integrated, compliance is more of a priority than ever before. The DYNAMIC+ framework is designed specifically keeping in mind compliance to major regulatory guidelines such as FDA's 21 CFR Part 11, EMA Annex 11, WHO guidelines, and ICH Q10. Not only does this offer compliance, but also prepares organizations for riding the waves of Pharma 4.0 successfully (Huma & Peng, 2023).

6.1. Compliance with FDA's 21 CFR Part 11

FDA's 21 CFR Part 11 regulates the use of valid electronic signatures and records. The DYNAMIC+ model enhances regulatory compliance through the requirement of a series of necessary mechanisms. For example, the Non-Repudiable principle employs blockchain technology to create time-stamped and immutable records with traceable and verifiable changes. This directly enhances the FDA's requirements for data integrity and accountability as represented in Figure 5 (Brody, 2016).

Furthermore, DYNAMIC+ facilitates extensive validation procedures and the use of AI-compliance checks to facilitate real-time monitoring. By incorporating such advanced technologies, organizations can provide ongoing compliance with regulations, minimizing the risk of non-compliance. The framework's emphasis on decentralization provides assurance that information is accessible and traceable across various locations, as required by the FDA for security and visibility (Debnath et al., 2023).

Figure 5. Components and definitions of FDA's ALCOA+ principles.

6.2. Conformance to EMA Annex 11

EMA Annex 11 reconciles conflicting demands placed on computer systems validated in clinical trials. DYNAMIC+ fulfills this need through strict validation processes ensuring the reliability and integrity of the system. The Autonomous factor in the system provides ongoing monitoring of system behavior, ensuring watchful regulatory compliance (Cambronero et al., 2024).

Other than that, addition of automated compliance checks using AI and machine learning yet again increases EMA's need for verifying data quality at regular intervals. Through audit log capture and capture of metadata, traceability is enhanced and documentation requirements according to EMA Annex 11 are facilitated so electronic processes are always strictly in accordance with regulatory guidelines.

6.3. Compliance with WHO Guidance

The World Health Organization (WHO) provides essential guidance for data integrity in pharmacy practice. DYNAMIC+ adheres to WHO best practice of contemporaneous recording and contemporaneous monitoring of the data. Decentralization of the management of data in the system is suitable for WHO promotion of transparency and accountability, particularly regarding global supply chains (World Health Organization, 2024).

With the use of IoT devices to obtain data on a real-time basis, WHO expectancy compliance is enhanced to enable organizations to track key manufacturing parameters in real-time. Real-time data management enables organizations to react immediately to any deviation for quality products and patient safety (Hightower & Pruett, 2019).

6.4. ICH Q10: Quality Management Systems

ICH Q10 brings an integrated framework of quality management for pharmaceuticals with the focus to deliver an active model for quality during product life. DYNAMIC+ stands on top of this model incorporating the Yield-Driven approach and linking data integrity to primary business and quality objectives. Compliance within such a case is regulation compliance but enhanced general operation performance (VanDuyse et al., 2021).

The Cognitive module of DYNAMIC+ enables predictive analytics capabilities to allow organizations to identify prospective quality issues early enough so that they can be prevented from growing into critical defects. Organizations leverage historic compliance data and trending analysis to take corrective action in advance, complementing ICH Q10's focus on ongoing improvement and successful risk management (Wigman & Ooi,2018).

6.5. A Roadmap for Transitioning to Pharma 4.0

DYNAMIC+ is an obligatory compliance guide for pharma companies in transition to Pharma 4.0. By overcoming the extremely specific requirements of regulatory authorities, it allows companies to leverage emerging technologies without sacrificing stringent guideline compliance. Decentralized operations, automated compliance tracking, and other security features not only provide better data integrity but allow companies to keep pace with the rapid speed of evolving regulatory landscapes (Schneikart et al., 2024).

Aside from this, DYNAMIC+ also promotes a culture of innovation and continuous improvement. Through feedback loops and adaptive methods, businesses are able to keep up with shifting regulations and advancing technologies. Not only does this vision-led approach create value for compliance, but it also keeps companies one step ahead as market leaders poised to deliver high-quality products of quality standards that regulators and patients demand (Reinhardt et al., 2020).

Regulatory harmonization is the need of the hour in today's fast-paced pharma industry to meet regulatory requirements and data integrity (Arief et al., 2022). DYNAMIC+ strategy is a holistic end-to-end solution of the regulations levied by powerful regulating bodies like the FDA, EMA, WHO, and ICH as mentioned in Table 1. Grounded on principles of transparency, automation, and quality management for forward orientation, DYNAMIC+ is not only compliant but also allows organizations to thrive in the era of Pharma 4.0. With the industry still under pressure to stay abreast of technology innovations, DYNAMIC+ is an informed step that balances regulatory demands and innovative practices ultimately to provide improved outcomes for patients and improved standards for industry (Pedro et al., 2023).

7. Implementation Roadmap for Transitioning to DYNAMIC+

The transition from baseline ALCOA+ to DYNAMIC+ model is cyclical. This would cause organizations to build data integrity in the Pharma 4.0 environment (Razzaq et al., 2023).

1. Conducting a Comprehensive Gap Analysis of current procedures and the DYNAMIC+ framework  is the beginning (Abdallah and Nizamuddin, 2023). This includes:

Weaknesses Identification: Determine where the current practice is lacking compared to the expectations created by Pharma 4.0, for instance, static controls for data or inadequate cyber security.

Regulatory Requirement Mapping: Plotting results against firm rules like the FDA and the EMA to effectively reflect loopholes.

Stakeholder Communication: Ties important stakeholders in the quality assurance department, IT department, operational teams, and attorneys together to decide and acquire stakeholder approval.

The above evaluation is constrained by the following installation phases and sets current limitations and opportunities.

2. Establishing Blockchain and AI-Based Compliance Mechanisms

Where there has existed a gap, firms must install blockchain and AI technologies (Karalis, 2024)

Blockchain Adoption: Employ decentralized, tamper-evident storage of data for non-repudiable evidence. This allows enhanced data integrity in clinical trials and multi-site business.

AI-driven Compliance Tools: Leverage or adopt AI-powered tools for automated data validation, audit trail monitoring, and real-time exception alert to reduce manual review.

These technologies are deeply compliance-focused and DYNAMIC+ guideline relevant.

3. Enhancing Cybersecurity Protocols to Align with Zero-Trust Models

Cybersecurity hardening is needed in today's threat environment (Rahman et al., 2024). This phase encompasses:

Implementation of Zero-Trust Policy: Mandate strict authentication of identity across all devices and users accessing assets, minimizing the chance of letting the wrong individuals through.

Continuous Monitoring: Mandate real-time anomaly detection controls to determine the likelihood of threats in real-time.

Data Encryption: Mandate end-to-end encryption on sensitive data in motion and at rest, keeping intrusions at bay.

These controls preserve data integrity and adhere to data security guidelines.

4- Empowering Employees with New Technology

Next-generation compliance technology training needs to be upskilled to current employees for leveraging the entire potential of DYNAMIC+ framework energy (Gou et al., 2024):

Design Training Program: Develop sample job role-based modules of DYNAMIC+ basics, blockchain, AI-based solutions, and cybersecurity best practices.

Hands-On Workshops: Develop hands-on employee workshops for new system introduction with experiential learning alternatives.

Continuous Learning Culture: Sustain continuous learning culture and compliances' technologies and regulatory updates awareness through the regular refresher training.

There must be specialized manpower to implement DYNAMIC+ properly.

5. Piloting DYNAMIC+ in High-Risk Areas Before Full-Scale Deployment

Roll out the DYNAMIC+ system pilot in high-risk sites before mass roll-out (Secinaro et al., 2021):

Piloting Sites: Choose where the risk of non-compliance is highest, i.e., complicated manufacturing stages or risky clinical trials.

Monitoring and Evaluation: Implement DYNAMIC+ practices in such sites and monitor performance against measures.

Feedback Loop: Leave open lines of feedback from employees during piloting so that the improvement process can begin immediately.

Pilot stage allows organizations to see areas of difficulty and get it right before roll-out.

ALCOA+ to DYNAMIC+ transition is a strategic step that should be prepared. Organizations can achieve solutions by adopting blockchain and AI technologies, better cybersecurity, employee training, and pilot implementation of high-risk areas by using gap analysis. Organizations can manage data integrity problems in the current era with the help of such solutions. This step aligns a firm to the rule and gets a firm ready for success in Pharma 4.0, which leads to better patient results and business results (Ding et al., 2018).

8. Future Outlook: The Role of AI, Blockchain & Pharma 5.0

As the pharma industry transforms into Pharma 5.0, new technologies like artificial intelligence (AI) and blockchain will transform drug development, manufacturing, and supply. Pharma 5.0 demands a networked, intelligent, and patient-focused approach through data-driven insight and transparency (Sah et al., 2024).

Artificial intelligence will transform the majority of the pharma operations, from drug discovery to personalized medicine. Machine learning can effectively search for lead drug candidates as well as optimize clinical trial designs and thereby achieve higher success rates and shorter time-to-market. AI will provide real-time monitoring and predictive maintenance for manufacturing, achieving optimized operational efficiency as well as product quality. The promise of AI in pharmacovigilance will also facilitate faster identification of adverse drug reactions through unstructured information analysis (Agrawal et al., 2024).

Blockchain technology provides data integrity and transparency in the form of un-hackable histories of transactions. What this translates to is perfect audit trails, which are pure gold when it comes to counterfeiting prevention and supply chain control. Use of blockchain technology in clinical trials has the potential to make patient consent easier as well as allow for secure sharing of data through the application of data encryption and further enhancing data integrity and data availability (Fraga-Lamas et al., 2024).

The synergy between blockchain and AI will create a healthier pharma ecosystem. Blockchain information can be interpreted by AI to improve supply chain decision-making, apart from facilitating personalized medicine through secure sharing of information. Pharma 5.0 will focus on patient engagement through the provision of health information and decision-making authority (Parry, 2024). AI-driven digital health technology will allow real-time health monitoring, with better treatment compliance and overall health. AI and blockchain in tandem will transform pharma business to a new horizon of data integrity, compliance, and patient care (Saveetha et al., 2024). Deployment will involve companies, regulators, and innovators' collaboration, and regulatory compliance, and this will push companies to the doorstep of the new healthcare ecosystem.

CONCLUSION 

Following the Data Integrity (DI) guidelines is the essence of quality assurance in the pharma industry and is required for product quality, efficacy, and safety. Although the ALCOA+ guidelines of the FDA have served as the bench-mark for analyzing and managing DI risks, a serious limitation exists in a Pharma 4.0 setting. The limitations include stringent data handling, no security focus, no reference to AI and automation, and no support to transition from paper to automated systems. This paper has introduced the DYNAMIC+ framework as a next-generation method that is grounded in ALCOA+ principles yet shatters these root problems. By incorporating technologies that facilitate cybersecurity, enable decentralized data management, and facilitate automation, DYNAMIC+ answers evolving regulatory agency needs such as the FDA and EMA. The implementation roadmap provided herein is the strategic implementation roadmap for DYNAMIC+ migration  . The paper also touches on standardization of data format and the application of new technology in mitigating DI risks. As the industry enters Pharma 5.0, AI, blockchain, and data analytics will be at the forefront to enable robust DI practices. Last but not least, the execution of the DYNAMIC+ framework will not only comply but best position biopharmaceutical firms for success in the new age of complex manufacturing that will increasingly define the industry.

REFERENCES

1. Abdallah, S. and Nizamuddin, N. (2023) Blockchain-Based Solution for Pharma Supply Chain Industry. Computers & Industrial Engineering, 177, 33-58.https://doi.org/10.1016/j.cie.2023.108997
2. Agrawal, A., Sharma, A., Srivastava, P. K., & Devi, M. S. (2024). Moving Towards Industry 5.0 for Sustainable Supply Chain in the Pharmaceutical Industry. In 2024 11th International Conference on Computing for Sustainable Global Development (INDIACom). New Delhi, India, 820-826.‏
3. Alosert, H., Savery, J., Rheaume, J., Cheeks, M., Turner, R., Spencer, C., ... & Goldrick, S. (2022). Data integrity within the biopharmaceutical sector in the era of Industry 4.0. Biotechnology Journal, 17(6), 21-26.‏
4. Arief, N. N., Gustomo, A., Roestan, M. R., Putri, A. N. A., & Islamiaty, M. (2022). Pharma 4.0: analysis on core competence and digital levelling implementation in pharmaceutical industry in Indonesia. Heliyon, 8(8): e10347.‏
5. Borgosz, L., & Dikicioglu, D. (2024). Industrial internet of things: What does it mean for the bioprocess industries?. Biochemical Engineering Journal, 201, 109-122.‏
6. Cambronero, M.E., Martínez, M.A., Llana, L., Rodríguez, R.J. and Russo, A. (2024) Towards a GDPR-Compliant Cloud Architecture with Data Privacy Controlled through Sticky Policies. PeerJ Computer Science , 10, e1819. https://doi.org/10.7717/peerj-cs.1898
7. Charitou, T., Lallas, E., Gerogiannis, V. C., & Karageorgos, A. (2024). A network modelling and analysis approach for pharma industry regulatory assessment. IEEE Access.‏12: 46470 – 46483.
8. Charoo, N. A., Khan, M. A., & Rahman, Z. (2023). Data integrity issues in pharmaceutical industry: Common observations, challenges and mitigations strategies. International journal of pharmaceutics, 631, 122503.‏
9. Chukwunweike, J. N., Praise, A., Osamuyi, O., Akinsuyi, S., & Akinsuyi, O. (2024). AI and Deep Cycle Prediction: Enhancing Cybersecurity while Safeguarding Data Privacy and Information Integrity. International Journal of Research Publication and Reviews, 5(8):22-31.‏
10. Debnath, B., Shakur, M. S., Bari, A. M., Saha, J., Porna, W. A., Mishu, M. J.,& Rahman, M. A. (2023). Assessing the critical success factors for implementing industry 4.0 in the pharmaceutical industry: implications for supply chain sustainability in emerging economies. Plos one, 18(6): e0287149.‏
11. Ding, B. (2018). Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains. Process Safety and Environmental Protection, 119, 115-130.‏
12. Durá, M., Sánchez-García, A., Sáez, C., Leal, F., Chis, A. E., González-Vélez, H., & García-Gómez, J. M. (2022). Towards a computational approach for the assessment of compliance of ALCOA+ Principles in pharma industry. In Challenges of Trustable AI and Added-Value on Health. 755-759. IOS Press.‏
13. FDA. (2018, August 10). Warning letter Kyowa Hakko Bio Co., Ltd. U.S. FOOD & DRUG ADMINISTRATION. https://www.fda.gov/ inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kyowa-hakko-bio-co-ltd-543924-08102018.
14. Fernsel, L., Kalff, Y., & Simbeck, K. (2024). Assessing the Auditability of AI-integrating Systems: A Framework and Learning Analytics Case Study. arXiv preprint arXiv:2411.08906.‏
15. Finelli, L. A., & Narasimhan, V. (2020). Leading a digital transformation in the pharmaceutical industry: reimagining the way we work in global drug development. Clinical pharmacology & therapeutics, 108(4), 756-761.‏
16. Fraga-Lamas, P., Fernández-Caramés, T. M., da Cruz, A. M. R., & Lopes, S. I. (2024). An overview of blockchain for Industry 5.0: towards human-centric, sustainable and resilient applications. IEEE Access. 12, 116162-116201.‏
17. Gou, F., Liu, J., Xiao, C., & Wu, J. (2024). Research on artificial-intelligence-assisted medicine: a survey on medical artificial intelligence. Diagnostics, 14(14): 1472.‏
18. Haleem, A., Javaid, M. and Khan, I.H. (2019) Current Status and Applications of Artificial Intelligence (AI) in Medical Field: An Overview. Current Medicine Research and Practice. 9: 231-237. https://doi.org/10.1016/j.cmrp.2019.11.005
19. Hammad, E., Nag, A. K., Chennamaneni, A., Aghashahi, M., & Dogdu, E. (2021, October). A deep-defense approach for next-gen cyber-resilient inter-dependent critical infrastructure systems. In 2021 Resilience Week (RWS), 9: 1-7.‏
20. Hightower, R., & Pruett, M. (2019). Data Integrity and Fundamental Responsibilities. In Good Manufacturing Practices for Pharmaceuticals, Seventh Edition. 22(3): 353-363.
21. Huang, J., O'Connor, T., Ahmed, K., Chatterjee, S., Garvin, C., Ghosh, K., ... & Warman, M. (2021). AIChE PD2M advanced process control workshop‐moving APC forward in the pharmaceutical industry. Journal of Advanced Manufacturing and Processing, 3(1): e10071.‏
22. Huma, T., & Peng, Z. (2023). Introduction to Regulatory Affairs and Different Regulatory Bodies for Pharmaceutical Products and Impact of Digitalization on Regulatory Affairs. Pharmacology & Pharmacy, 14(11): 463-477.‏
23. Idouglid, L., Tkatek, S., Elfayq, K., & Guezzaz, A. (2024). Next-gen security in IIoT: integrating intrusion detection systems with machine learning for industry 4.0 resilience. International Journal of Electrical & Computer Engineering, 14(3): 2088-8708.‏
24. Isoko, K., Cordiner, J. L., Kis, Z., & Moghadam, P. Z. (2024). Bioprocessing 4.0: a pragmatic review and future perspectives. Digital Discovery, 3(9): 1662-1681.‏
25. Isoko, K., Cordiner, J. L., Kis, Z., & Moghadam, P. Z. (2024). Bioprocessing 4.0: a pragmatic review and future perspectives. Digital Discovery, 3(9), 1662-1681.‏
26. Karalis, V. D. (2024). The integration of artificial intelligence into clinical practice. Applied Biosciences, 3(1), 14-44.‏
27. Kavasidis, I., Lallas, E., Gerogiannis, V. C., & Karageorgos, A. (2022, April). Analytics and blockchain for data integrity in the pharmaceuticals industry. In 2022 4th International Conference on Advances in Computer Technology, Information Science and Communications (CTISC), 22(4):1-5.
28. Kodumuru, R., Sarkar, S., Parepally, V., & Chandarana, J. (2025). Artificial Intelligence and Internet of Things Integration in Pharmaceutical Manufacturing: A Smart Synergy. Pharmaceutics 2025, 17, 290. Health.‏
29. Kulkarni, P., & Kothari, C. (2024). Documentation and Data Integrity in Pharmaceutical Industry. In Modern Aspects of Pharmaceutical Quality Assurance: Developing & Proposing Application models, SOPs, practical audit systems for Pharma Industry. Singapore: Springer Nature Singapore.‏ 22(3): 381-403.
30. Leach, C. D. (2024). Enhancing Data Governance Solutions to Optimize ALCOA+ Compliance for Life Sciences Cloud Service Providers (Doctoral dissertation, Colorado Technical University).‏
31. Lin, L., Athe, P., Rouxelin, P., Avramova, M., Gupta, A., Youngblood, R., ... & Dinh, N. (2022). Digital-twin-based improvements to diagnosis, prognosis, strategy assessment, and discrepancy checking in a nearly autonomous management and control system. Annals of Nuclear Energy, 166, 108715.‏
32. Malviya, N., Malviya, S., & Dhere, M. (2023). Transformation of pharma curriculum as per the anticipation of pharma industries-need to empower fresh breeds with globally accepted pharma syllabus, soft skills, ai and hands-on training. Indian Journal of Pharmaceutical Education and Research, 57(2): 320-328.‏
33. Manzano, T., & Langer, G. (2018). Getting ready for pharma 4.0. Pharm Eng, 38, 72-9.‏
34. McDermott, O., Wojcik, A. M., Trubetskaya, A., Sony, M., Antony, J., & Kharub, M. (2024). Pharma industry 4.0 deployment and readiness: a case study within a manufacturer. The TQM Journal, 36(9), 456-476.‏
35. Mustapää, T., Nummiluikki, J., & Viitala, R. (2022). Digitalization of calibration data management in pharmaceutical industry using a multitenant platform. Applied Sciences, 12(15), 7531-7661.‏
36. Ntamo, D., Lopez-Montero, E., Mack, J., Omar, C., Highett, M. I., Moss, D., ... & Zandi, M. (2022). Industry 4.0 in action: Digitalisation of a continuous process manufacturing for formulated products. Digital Chemical Engineering, 3, 100025.‏
37. Oliveira, M. A., Manara, S., Molé, B., Muller, T., Guillouche, A., Hesske, L., ... & Berger, C. R. (2023). Semantic Modelling of Organizational Knowledge as a Basis for Enterprise Data Governance 4.0--Application to a Unified Clinical Data Model. arXiv preprint arXiv:2311.02082.‏
38. Omar, I. A., Jayaraman, R., Salah, K., Simsekler, M. C. E., Yaqoob, I., & Ellahham, S. (2020). Ensuring protocol compliance and data transparency in clinical trials using Blockchain smart contracts. BMC Medical Research Methodology, 20, 1-17.‏
39. Padmanaban, H. (2024). Revolutionizing regulatory reporting through AI/ML: Approaches for enhanced compliance and efficiency. Journal of Artificial Intelligence General science (JAIGS) ISSN: 3006-4023, 2(1), 71-90.‏
40. Parry, G. M. (2024). Blockchain Technology: Enabling Decentralized and Secure Industrial Processes in Industry 5.0. In Industry 5.0 and Emerging Technologies: Transformation Through Technology and Innovations , 5(7): 259-296. Cham: Springer Nature Switzerland.‏
41. Pedro, F., Veiga, F., & Mascarenhas-Melo, F. (2023). Impact of GAMP 5, data integrity and QbD on quality assurance in the pharmaceutical industry: How obvious is it?. Drug Discovery Today, 28(11), 103759.‏
42. Pesqueira, A., & Sousa, M. J. (2024). Exploring the role of big data analytics and dynamic capabilities in ESG programs within pharmaceuticals. Software Quality Journal, 32(2), 607-640.‏
43. Porwol, L., Pereira, A. G., & Dumas, C. (2022). Transforming e-participation: VR-dialogue–building and evaluating an AI-supported framework for next-gen VR-enabled e-participation research. Transforming Government: People, Process and Policy, 17(2), 233-250.‏
44. Rahman, M. A., Victoros, E., Ernest, J., Davis, R., Shanjana, Y., & Islam, M. R. (2024). Impact of artificial intelligence (AI) technology in healthcare sector: a critical evaluation of both sides of the coin. Clinical Pathology, 17, 2632010X241226887.‏
45. Rasool, S., Ali, M., Hussain, H. K., & Gill, A. Y. (2023). Unlocking the potential of healthcare: AI-driven development and delivery of vaccines. International Journal of Social, Humanities and Life Sciences, 1(1), 29-37.‏
46. Razzaq, A., Sharif, A., Ozturk, I., & Afshan, S. (2023). Dynamic and threshold effects of energy transition and environmental governance on green growth in COP26 framework. Renewable and Sustainable Energy Reviews, 17(9), 113-296.‏
47. Reinhardt, I. C., Oliveira, J. C., & Ring, D. T. (2020). Current perspectives on the development of industry 4.0 in the pharmaceutical sector. Journal of Industrial Information Integration, 18, 100-131.‏
48. Robert, L. (2023). Integrating AI and IAM for Comprehensive Cybersecurity in GxP-Regulated Healthcare Environments.‏
49. Sabale, M. M., Pande, V. A., Tagalpallewar, A. A., Swami, A. G., Pawar, A. T., & Baheti, A. M. (2024). Maintaining data safety and accuracy through data integrity (DI): A comprehensive review. Research Journal of Pharmacy and Technology, 17(5), 2431-2440.‏
50. Sah, B. P., Hasan, M. M., Shofiullah, S., & Faysal, S. A. (2024). AI-Driven IoT And Blockchain Integration In Industry 5.0 A Systematic Review Of Supply Chain Transformation. Innovatech Engineering Journal, 1(01), 99-116.‏
51. Saveetha, D., Ponnusamy, V., Zdravković, N., & Nandini, S. M. (2024). Blockchain Application in Industry 5.0. Artificial Intelligence‐Enabled Digital Twin for Smart Manufacturing, 421-442.‏
52. Schneikart, G., Mayrhofer, W., Löffler, C., & Frysak, J. (2024). A roadmap towards circular economies in pharma logistics based on returnable transport items enhanced with Industry 4.0 technologies. Resources, Conservation and Recycling, 20(6), 107-215.‏
53. Secinaro, S., Calandra, D., Secinaro, A., Muthurangu, V., & Biancone, P. (2021). The role of artificial intelligence in healthcare: a structured literature review. BMC medical informatics and decision making, 21, 1-23.‏
54. Singh, S. (2017, December). Optimize cloud computations using edge computing. In 2017 International Conference on Big Data, IoT and Data Science (BID) ,3(4): 49-53.
55. Smiatek, J., Jung, A., & Bluhmki, E. (2020). Towards a digital bioprocess replica: computational approaches in biopharmaceutical development and manufacturing. Trends in Biotechnology, 38(10), 1141-1153.‏
56. Steinwandter, V., Borchert, D., & Herwig, C. (2019). Data science tools and applications on the way to Pharma 4.0. Drug discovery today, 24(9), 1795-1805.‏
57. Tabasevic, I., Milanovic, D. D., Spasojevic Brkic, V., Misita, M., & Zunjic, A. (2024). Cybernetic Model Design for the Qualification of Pharmaceutical Facilities. Applied Sciences, 14(13), 55-65.‏
58. Ullagaddi, P. (2024). Safeguarding Data Integrity in Pharmaceutical Manufacturing. Journal of Advances in Medical and Pharmaceutical Sciences, 26(8), 64-75.‏
59. van Loen, H., Badio, M., & Van Herrewege, Y. (2024). 35 Data Management in Emergency Response Research. In Principles and Practice of Emergency Research Response, 33: 909-937. Cham: Springer International Publishing.‏
60. VanDuyse, S. A., Fulford, M. J., & Bartlett, M. G. (2021). ICH Q10 pharmaceutical quality system guidance: understanding its impact on pharmaceutical quality. The AAPS journal, 23, 1-11.‏
61. Vento, T. (2021). Systematic specification of requirements for assembly process control system in the pharmaceutical industry (Master's thesis, T. Vento).‏
62. Wigman, L., & Ooi, D. (2018). ICH Q10 Quality Systems. ICH Quality Guidelines, 611.‏
63. Wölfle, R., Amaral, I. A. S., & Teixeira, L. (2022). Pharma in the context of industry 4.0‐challenges and opportunities based on literature review. In Proceedings of the 5th European International Conference on Industrial Engineering and Operations Management Rome, Italy 4, 1038-1050.‏
64. World Health Organization. (2024). Quality assurance of pharmaceuticals: a compendium of guidelines and related materials, Volume 1. Good practices and related regulatory guidance. World Health Organization.‏
65. Yaseen, Kwon, O. J., Kim, J., Jamil, S., Lee, J., & Ullah, F. (2024). Next-Gen Dynamic Hand Gesture Recognition: MediaPipe, Inception-v3 and LSTM-Based Enhanced Deep Learning Model. Electronics, 13(16), 3233.‏